18 completed, 11 recruiting, 5 not yet recruiting, 4 active not recruiting. 22 Not applicable, 12 Phase 2, 6 Phase 1, 2 Early Phase 1, 1 Phase 3.
Follow Methamphetamine Use Disorder: new trials by email Literature Review of Methamphetamine Use Disorder trials Research Report on Methamphetamine Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin for Methamphetamine Use Disorder Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct)., Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions). - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Peter Hendricks | 42 | 2027-02-01 | 2026-09-21 |
| Transcranial Magnetic Stimulation for Methamphetamine Use Disorder During Pregnancy 4- Week Dual-Target Transcranial Magnetic Stimulation (TMS), Accelerated Dual-Target Transcranial Magnetic Stimulation (aTMS), Treatment as Usual (TAU) - Methamphetamine Use Disorder, Pregnancy | Not applicable | Not yet recruiting | University of Utah | 45 | 2026-12-01 | 2026-11-05 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Phase 2 | Recruiting | Nicky Mehtani, MD, MPH | 30 | 2026-12-01 | 2026-11-09 |
| Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder Tirzepatide, Placebo (saline) - Methamphetamine Use Disorder | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 228 | 2026-10-23 | 2026-10-26 |
| Closed-loop TMS for the Core Clinical Features of Methamphetamine Use Disorder Closed-loop TMS, Conventional TMS, Random TMS - Methamphetamine Use Disorder, Substance Use Disorder | Not applicable | Not yet recruiting | Shanghai Mental Health Center | 21 | 2026-10-01 | 2026-11-02 |
| Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study 12 weeks of weekly subcutaneous semaglutide injection - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Kirby Institute | 40 | 2026-09-01 | 2026-06-26 |
| An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Tirzepatide - Obesity, Methamphetamine Use Disorder | Phase 2 | Active not recruiting | University of Texas Southwestern Medical Center | 45 | 2026-08-19 | 2026-10-29 |
| Closed-loop TBS Targeting rPO for the Core Clinical Features of Methamphetamine Use Disorder Closed-loop Theta-Burst Stimulation (TBS) Targeting rPO - Methamphetamine Use Disorder, Substance Use Disorder | Not applicable | Active not recruiting | Shanghai Mental Health Center | 5 | 2026-08-05 | 2026-11-02 |
| Methamphetamine Use Disorder Support in Heart Failure Pilot Study MUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management - Heart Failure, Methamphetamine Use Disorder | Not applicable | Not yet recruiting | University of Southern California | 50 | 2026-05-31 | 2026-05-04 |
| LDART for Stimulant Use Disorder LDART, Psychoeducational booklet - Stimulant Use Disorder, Cocaine Use Disorder | Not applicable | Enrolling by invitation | Yale University | 80 | 2026-04-29 | 2026-05-01 |
| CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM CHAMPION Intervention, Delayed CHAMPION Package - PrEP Adherence, Methamphetamine Use Disorder | Not applicable | Recruiting | University of California, San Diego | 100 | 2026-04-24 | 2026-08-26 |
| Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i Contingency management - Contingency Management, Methamphetamine Use Disorder | Not applicable | Withdrawn | Queen's Medical Center | 2026-04-01 | 2026-09-18 | |
| Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia Theta Burst Stimulation, Cognitive Behavioral Therapy - Methamphetamine Use Disorder, Theta Burst Stimulation | Not applicable | Completed | Universitas Indonesia | 22 | 2026-03-23 | 2026-09-16 |
| Non-Abstinence Outcomes in Methamphetamine Use Disorder Contingency Management - Methamphetamine Use Disorder | Not applicable | Recruiting | William Stoops | 300 | 2026-01-14 | 2026-06-08 |
| LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis Methamphetamine Use Disorder, Methamphetamine-induced Psychosis | Completed | Elazığ Mental Health and Diseases Hospital | 111 | 2025-09-01 | 2026-09-10 | |
| Methamphetamine and Troriluzole Placebo, Methamphetamine - Methamphetamine Use Disorder | Early Phase 1 | Recruiting | William Stoops | 40 | 2025-08-25 | 2026-06-08 |
| Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder LDX-01 plus TAU, Placebo plus TAU - Methamphetamine Abuse, Methamphetamine-dependence | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 80 | 2025-07-18 | 2026-02-23 |
| α-N-acetylgalactosaminidase in Methamphetamine Psychosis Methamphetamine Use Disorder, Methamphetamine-induced Psychosis | Completed | Elazığ Mental Health and Diseases Hospital | 93 | 2025-05-01 | 2026-02-25 | |
| ECG Findings in Methamphetamine Use Methamphetamine Use Disorder, Methamphetamine Induced Psychosis | Recruiting | Elazığ Mental Health and Diseases Hospital | 240 | 2025-04-07 | 2026-09-10 | |
| Psilocybin for Methamphetamine Addiction Psilocybin 25 mg - Methamphetamine Use Disorder | Early Phase 1 | Recruiting | Kevin Murnane | 20 | 2025-04-04 | 2025-10-07 |
Showing 20 of 45. Sign in to see all of them.
Substance-Related Disorders (9) · Behavior, Addictive (3) · Obesity (2) · Overweight (2) · Psychotic Disorders (2) · Acquired Immunodeficiency Syndrome (1) · Amphetamine-Related Disorders (1) · Cardiovascular Abnormalities (1) · Chemically-Induced Disorders (1) · Chemsex (1) · Cocaine-Related Disorders (1) · Heart Failure (1) · Recurrence (1) · Sexual Behavior (1) · Sleep Initiation and Maintenance Disorders (1)
Mental Disorders (14) · Chemically-Induced Disorders (10) · Behavior (4) · Compulsive Behavior (3) · Impulsive Behavior (3) · Pathological Conditions, Signs and Symptoms (3) · Body Weight (2) · Cardiovascular Diseases (2) · Nutrition Disorders (2) · Nutritional and Metabolic Diseases (2) · Overnutrition (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Signs and Symptoms (2) · Substance-Related Disorders (2) · Blood-Borne Infections (1)
Methamphetamine (4) · Psilocybin (4) · Tirzepatide (3) · Naltrexone (2) · Therapeutics (2) · Transcranial Magnetic Stimulation (2) · Bupropion (1) · Cognitive Behavioral Therapy (1) · Duloxetine Hydrochloride (1) · Floors and Floorcoverings (1) · Injections (1) · Ketamine (1) · Lactose (1) · Methylphenidate (1) · Mirtazapine (1)
Shanghai Mental Health Center (5) · University of Texas Southwestern Medical Center (4) · Elazığ Mental Health and Diseases Hospital (3) · Nicky Mehtani, MD, MPH (2) · Queen's Medical Center (2) · The University of Texas Health Science Center, Houston (2) · Turning Point (2) · University of Colorado, Denver (2) · William Stoops (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Craig Rush (1) · Denver Health and Hospital Authority (1) · Glenn-Milo Santos (1) · Hanoi Medical University (1) · Icahn School of Medicine at Mount Sinai (1)
United States (30) · China (5) · Australia (3) · Turkey (Türkiye) (3) · Canada (1) · Indonesia (1) · Vietnam (1)
Glenn-Milo Santos, PhD, MPH (2) · Heather Webber, PhD (2) · Madhukar Trivedi, MD (2) · Manish Jha, M.B.B.S. (2) · Min Zhao, PhD (2) · Alia A Al-Tayyib, PhD (1) · Christopher Nicholas, PhD (1) · Claudia B Padula, PhD (1) · Dan I Lubman (1) · Didier Jutras-Aswad, MD (1) · Giang M. Le, MD, PhD (1) · Kathleen M Grant, MD (1) · Kathleen T Brady, MD PHD (1) · Keith Heinzerling, MD (1) · Kevin S Murnane, PhD (1)
PMID 30724759, PMID 33497547, PMID 36991490, PMID 37245855, PMID 37377462, PMID 38665252, PMID 38856086, PMID 39731508, PMID 40336040, PMID 40623319, PMID 40767786, PMID 40850924, PMID 42180350, PMID 42504048, PMID 42684700
1DP2DA066200 (1), 1UG3DA067126 (1), 2025 (1), 2KL2TR001870 (1), K23DA065955 (1), K24DA058882 (1), R01CE003363 (1), R01DA043238 (1), R01DA047391 (1), R01DA050486 (1), R01DA053171 (1), R01DA060632 (1), R01DA064144 (1), R21DA060856 (1), R61DA056779 (1)